TG and breast cancer: Subjects with breast cancer reported significantly worse fatigue symptoms than age-matched controls, as indicated by higher disruption index, justifying a need to screen this patient population at start of treatment as well as serially post-treatment to evaluate the need for thyroid hormone replacement and providing for a novel strategy for treating chemotherapy-induced fatigue.